Actively Recruiting
Disease Characteristics of IR-CAD: a Case-control Study
Led by Peking Union Medical College Hospital · Updated on 2025-11-19
30
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD and 10 patients with AS-CAD.
CONDITIONS
Official Title
Disease Characteristics of IR-CAD: a Case-control Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Case group (IR-CAD patients): 18 years of age or older, male or female.
- Negative urine or blood pregnancy test for females with childbearing potential.
- Prior history of coronary revascularization (PCI or CABG).
- Receiving standard treatment for secondary prevention of AS-CAD after the last coronary revascularization.
- Hospitalized due to rapidly-progressive myocardial ischemia with typical angina symptoms and non-invasive evidence.
- Myocardial ischemia occurred within 6 months or on immunosuppressive therapy within 12 months of last coronary revascularization.
- Angiographic evidence of new coronary lesions relevant to myocardial ischemia.
- Evidence of inflammation indicated by elevated inflammation markers, established autoimmune or vasculitis diagnosis, or immunosuppressive therapy.
- Control group (AS-CAD patients): Aged 45 to under 65 years, male or female.
- Negative urine or blood pregnancy test for females with childbearing potential.
- Currently 12±6 months after the last PCI.
- Receiving standard treatment for secondary prevention of AS-CAD after last PCI.
- Coronary angiography and/or optical coherence tomography performed during current hospitalization.
- No evidence of rapidly-progressive myocardial ischemia.
- No angiographic evidence of new coronary lesions relevant to myocardial ischemia.
You will not qualify if you...
- Coronary restenosis due to mechanical factors (stent issues).
- Moderate to severe heart diseases such as congenital heart disease, valvular diseases, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, or arrhythmia.
- Active acute or chronic infection including HIV or tuberculosis.
- Active malignancy diagnosed within 12 months or requiring ongoing treatment.
- Vital organ failure.
- Life expectancy less than 1 year.
- Contraindications or intolerance to treatments for secondary prevention of AS-CAD, contrast agents, glucocorticoids, or immunosuppressive agents.
- Pregnancy, breastfeeding, or intention to become pregnant during the study.
- Risk of non-compliance such as drug addiction or alcohol abuse.
- Previous enrollment in this study.
- Participation in another study within the past 30 days.
- Involvement in the planning or conduct of this study.
- Any condition making participation unsuitable as judged by investigators.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Z
Zhenyu Liu, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here